Skip to content
Peptigraph home

GLOW Side Effects: What Studies and Users Report

What FDA labels and clinical studies report for GLOW, how strong that evidence is, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureThree-peptide blendUpdated

Side effects reported in studies

Side effects reported in published studies, strongest design first. Frequencies are quoted as the source gives them; animal results are labelled. No study has tested GLOW itself; rows are for each ingredient.

Side effects of GLOW in labels and published studies
Side effectHow commonStudy typeSource
TB-500: Adverse events“The adverse events were mild to moderate in intensity.”Frequency not statedHuman RCTJournal of cellular and molecular medicine 2021, PMID 34346165
TB-500: Treatment-emergent adverse events“Adverse events were infrequent, and mild or moderate in intensity.”Frequency not statedHuman RCTn = 40Annals of the New York Academy of Sciences 2010, PMID 20536472
TB-500: Safety profile“The safety profile of all doses of administered Tbeta4 was deemed acceptable and comparable to placebo.”Frequency not statedHuman RCTn = 73Annals of the New York Academy of Sciences 2010, PMID 20536470
BPC-157: Side effects“The BPC-157 peptide infusion was tolerated, with no side effects reported.”Frequency not statedHuman uncontrolled trialn = 2Alternative therapies in health and medicine 2025, PMID 40131143
BPC-157: Adverse events overall“No one dropped out of the study, and no adverse events were reported.”Frequency not statedHuman uncontrolled trialn = 12Alternative therapies in health and medicine 2024, PMID 39325560
GHK-Cu: Tolerability“Treatment was well tolerated.”Frequency not statedHuman uncontrolled trialn = 1000Journal of cosmetic and laser therapy 2018, PMID 29482481
GHK-Cu: Adverse effects“There was no adverse effect during and after treatment.”Frequency not statedHuman case reportn = 1Journal of cosmetic and laser therapy 2016, PMID 27064823

What is not known

  • How common each effect is at the doses people use outside of studies.
  • Effects that take longer to appear than the length of the published studies.
  • How GLOW interacts with other medicines and supplements.
  • Whether research-grade products, which are not checked by the FDA, behave like the material used in studies.

When to get medical help

Get urgent care for: trouble breathing, swelling of the face or throat, a widespread rash, severe or lasting stomach pain, fainting, or an injection site that becomes hot, red and spreading.

This is not a complete list. A doctor or pharmacist can help you judge whether a symptom is related.

Common questions

What are the side effects of GLOW?

Studies we summarise reported adverse events, treatment-emergent adverse events, safety profile. The table on this page gives how often each happened and links each source.

Is GLOW safe?

GLOW has an FDA-approved label that lists its known risks. That label covers the approved product used as prescribed, not compounded or research-chemical versions.

Is GLOW banned in sport?

Yes. Prohibited by WADA (S0). Tested athletes should not use it.

More on GLOW

DosageDoses used in published studies, with the source for each.Blend calculatorSplit a blend vial into per-peptide amounts and units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.How to injectSites, syringe types and hygiene, step by step.StoragePowder and mixed vials: temperature and shelf life.

Sources

  1. 1A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
  2. 2A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.Annals of the New York Academy of Sciences · 2010PMID 20536472Accessed 2 Oct 2026
  3. 3The effect of thymosin treatment of venous ulcers.Annals of the New York Academy of Sciences · 2010PMID 20536470Accessed 2 Oct 2026
  4. 4Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
  5. 5Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
  6. 6Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2018PMID 29482481Accessed 2 Oct 2026
  7. 7Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation).Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2016PMID 27064823Accessed 2 Oct 2026

Found an error? Report a correction.